Skip to main content

Security report for amgen.be

Amgen · Healthcare · Belgium

Low risk. 3 critical or high findings in Email security and SSL/TLS.

Security score

76/100

Risk levelLow

0–100, higher is better. How it is calculated

Amgen is a global leader in biotechnology, focusing on innovative medicines and healthcare solutions. The website presents a professional and comprehensive digital presence targeting healthcare professionals, patients, and partners. The technical infrastructure includes modern JavaScript libraries such as VideoJS and Cookiebot for video and cookie consent management, respectively, with Google Tag Manager for analytics and marketing. Security posture is strong with HTTPS enforced and content security policies in place, though additional headers could enhance protection. Privacy compliance is robust, with clear GDPR adherence and cookie consent mechanisms. Overall, the website reflects a mature enterprise-level digital asset with high trustworthiness and professionalism.

Scanned

NIS2 and GDPR posture

GDPR outside view
100/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

3 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

    • High

      No SPF record found

      SPF helps prevent email spoofing

      What to do: Add SPF record: "v=spf1 include:_spf.yourmailprovider.com ~all"

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching amgen.be

This scan found 19 issues across 5 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
77
Security headers
80
Email security
40
DNS health
60
Network security
100
GDPR outside view
100
Average
76

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Amgen operates in the healthcare sector as a biotechnology pharmaceutical company. The website content and metadata emphasize innovation and global leadership. The business model revolves around research, development, and commercialization of biotech medicines. The target audience includes healthcare professionals and patients in Belgium, with compliance to EU regulations. The company maintains a consistent brand image and demonstrates strong compliance and trust indicators. No suspicious or unrelated domains were found linked. The lack of public WHOIS data is typical for large corporations protecting privacy.

Security posture

The website employs HTTPS with a good SSL configuration and a Content-Security-Policy header to upgrade insecure requests. Cookie consent is managed via Cookiebot, indicating attention to privacy and compliance. No critical vulnerabilities or exposed sensitive data were detected in the HTML content. However, security headers like HSTS, X-Frame-Options, and X-XSS-Protection are not explicitly observed and could be added to strengthen security. No incident response or security policy pages were found, which could be improved for transparency. Overall, the security posture is strong but could benefit from additional headers and documented incident response.

Recommendations

  1. Implement additional security headers such as HSTS, X-Frame-Options, and X-XSS-Protection.
  2. Publish a clear security policy and incident response information on the website.
  3. Enhance transparency by providing more detailed business contact information including phone numbers and physical addresses.
  4. Regularly audit third-party scripts and tracking tools to minimize privacy risks.
  5. Maintain WHOIS data accuracy and consider publishing registrant information if possible to improve trust.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Amgen
Description
Ontdek Amgen, een wereldwijde pionier in de biotechnologie die de gezondheidszorg transformeert. Leer meer over onze innovatieve geneesmiddelen en biotech vooruitgang die wereldwijd levens verbetert.
Key services
Innovative medicines, Biotech research, Healthcare solutions
Content quality
excellent
Branding
consistent

Technology

Stack
JavaScript, VideoJS, Cookiebot, Google Tag Manager
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent mechanism
  • No exposed sensitive data in HTML

Analytics and tracking

Services
Google Tag Manager
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Cookiebot
Transparency
good

Site quality

Design
excellent
User experience
excellent
Content relevance
excellent
Navigation
excellent
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is fully accessible with rich content
  2. Strong compliance with GDPR and cookie consent
  3. Professional healthcare industry focus
  4. No security blocking or WAF challenge detected
  5. WHOIS data is restricted, common for corporate domains
  6. Use of modern JavaScript libraries and tracking tools
Technical notes

Notes

The website uses modern JavaScript libraries including VideoJS for media playback and Cookiebot for cookie consent management, integrated with Google Tag Manager for analytics and marketing. The site is responsive and optimized for mobile devices with good accessibility features. Performance is moderate, with some room for improvement in loading speed. The CMS or hosting provider is not explicitly identified. SEO is supported by appropriate meta tags and Open Graph data. The site uses a Content-Security-Policy header to enforce security. Overall, the technical implementation is solid with opportunities for further optimization and security hardening.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with amgen.be. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review amgen.be.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.